TrialThe oncologist2026

Phase IB/II study of alpelisib combined with paclitaxel in patients with PIK3CA-altered metastatic or recurrent gastric cancer.

Ji-Won Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.